In brief
Dr. Tracy Beth Hoeg has been dismissed from her role at the FDA amid a leadership overhaul that has seen the resignation of other key figures, including FDA Commissioner Marty Makary. Hoeg's leadership came under scrutiny for her investigations into the safety of antidepressants and COVID-19 vaccines. The move highlights continued discontent among political allies and various health groups regarding the agency's direction.
Washington (AP) — In a significant shake-up at the Food and Drug Administration (FDA), Dr. Tracy Beth Hoeg has been removed from her role overseeing the agency's drug program. The move comes as part of broader changes at the FDA, which have included the resignation of Commissioner Marty Makary earlier in the week.
Hoeg indicated on social media that she was 'fired' and expressed that she leaves the agency without regrets. Her exit is part of an ongoing reshuffling of leadership positions, which has caused unrest and dissatisfaction among political allies and health advocacy groups.
Dr. Mike Davis, deputy director of the FDA's drug programs, has been appointed as her replacement. Mikhail Karim will take over as acting head of the vaccine division. These leadership changes follow criticism of the agency's handling of crucial health issues, including the safety of antidepressants and the efficacy of COVID-19 vaccinations.
During her brief tenure leading the drug center, Hoeg was closely aligned with Makary and Health Secretary Robert F. Kennedy Jr., albeit her management experience was notably limited compared to typical FDA center directors.
Hoeg had been at the forefront of various investigations into the safety of widely used therapies and vaccines, including ongoing concerns regarding adverse effects associated with COVID-19 shots. She had previously criticized government health measures related to the pandemic, drawing attention as a critic of masks and vaccine mandates.
The changes at the FDA not only involve personnel shifts but signify a larger struggle regarding the agency's direction and responsiveness to public health advocacy and political pressures. Stakeholders are left observing how these changes will impact regulatory practices and public health policy moving forward.
